Anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatments being developed for Covid-19 are expected to have better therapeutic effects than cytokine-specific therapies such as interleukin (IL)-6 and IL-1 inhibitors.

These antibodies target an earlier point in the inflammation pathway than inhibitors that target cytokines like IL-6 and IL-1. Therefore, they could have a broader and better therapeutic response. Read more here.